Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
Total Valuation
BioRestorative Therapies has a market cap or net worth of $12.83M. The enterprise value is -$823.12K.
Market Cap$12.83M
Enterprise Value-$823.12K
Share Statistics
BioRestorative Therapies has 7,504,780 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,504,780
Owned by Insiders16.94%
Owned by Institutions1.58%
Financial Efficiency
BioRestorative Therapies’s return on equity (ROE) is -1.05 and return on invested capital (ROIC) is -135.44%.
Return on Equity (ROE)-1.05
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-135.44%
Return on Capital Employed (ROCE)-1.35
Revenue Per Employee36.45K
Profits Per Employee-816.31K
Employee Count11
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioRestorative Therapies is -1.24. BioRestorative Therapies’s PEG ratio is 0.02.
PE Ratio-1.24
PS Ratio32.31
PB Ratio1.30
Price to Fair Value1.30
Price to FCF-1.35
Price to Operating Cash Flow-1.35
PEG Ratio0.02
Income Statement
In the last 12 months, BioRestorative Therapies had revenue of 401.00K and earned -8.98M in profits. Earnings per share was -1.16.
Revenue401.00K
Gross Profit372.93K
Operating Income-11.56M
Pretax Income-8.98M
Net Income-8.98M
EBITDA-11.56M
Earnings Per Share (EPS)-1.16
Cash Flow
In the last 12 months, operating cash flow was -7.66M and capital expenditures -163.78K, giving a free cash flow of -7.82M billion.
Operating Cash Flow-7.66M
Free Cash Flow-7.82M
Free Cash Flow per Share-1.04
Dividends & Yields
BioRestorative Therapies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change37.90%
50-Day Moving Average1.76
200-Day Moving Average1.70
Relative Strength Index (RSI)46.32
Average Volume (3m)41.25K
Important Dates
BioRestorative Therapies upcoming earnings date is May 20, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
BioRestorative Therapies as a current ratio of 2.97, with Debt / Equity ratio of 0.42%
Current Ratio2.97
Quick Ratio2.97
Debt to Market Cap0.00
Net Debt to EBITDA0.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BioRestorative Therapies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BioRestorative Therapies EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -1.28.
EV to Sales26.32
EV to EBITDA-0.91
EV to Free Cash Flow-1.28
EV to Operating Cash Flow-1.28
Balance Sheet
BioRestorative Therapies has $13.09M in cash and marketable securities with $268.36K in debt, giving a net cash position of -$13.05M billion.
Cash & Marketable Securities$13.09M
Total Debt$268.36K
Net Cash-$13.05M
Net Cash Per Share-$1.74
Tangible Book Value Per Share$1.02
Margins
Gross margin is 70.78%, with operating margin of -2881.59%, and net profit margin of -2239.25%.
Gross Margin70.78%
Operating Margin-2881.59%
Pretax Margin-2239.25%
Net Profit Margin-2239.25%
EBITDA Margin-2881.59%
EBIT Margin0.00%
Analyst Forecast
The average price target for BioRestorative Therapies is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside367.84% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast175.03%
EPS Growth Forecast55.34%